Riskpilot← Back to searchSign inGet full accessMoberg Pharma AB (publ)
ABActiveOrg 5566977426Gustavslundsvägen 42Research and experimental development on natural sciences and engineering · NACE 7210Est. 20065-9 employees
Revenue 2024
—
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2024
—
| Revenue | — | — |
| EBITDA | SEK 0 | — |
| Net profit | — | — |
| Total assets | — | — |
| Equity | — | — |
| Employees | — | — |
Legal name
Moberg Pharma AB (publ)
Org number
5566977426
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
31 januari 2006
Share capital
SEK 46 693 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av en av ledamöterna i förening med Ljung, Anna Helena Constance Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva utveckling, tillverkning, direkt och indirekt försäljning, marknadsföring och licensiering av läkemedel, medicintekniska produkter och hudvårdsprodukter samt därmed förenlig verksamhet.
Address
Gustavslundsvägen 42
Phone
+46852230700
Email
info@mobergpharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 50 488 | 0 | 207 | 0 | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | 14 826 | −19 521 | −20 226 | −27 463 | 0 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 14 826 | −19 521 | −20 226 | −27 463 | 0 |
| Net financials | −3 575 | −240 | 714 | 2 043 | — |
| Profit before tax | 12 251 | −19 761 | −19 512 | −25 420 | 0 |
| Tax | −2 976 | 3 703 | 3 802 | 4 327 | — |
| Net profit | 9 275 | −16 058 | −15 710 | −21 093 | — |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 514 080 | 450 989 | 564 523 | 634 832 | — |
| Equity | 449 632 | 434 052 | 533 585 | 610 726 | — |
| Long-term debt | 4 818 | 1 300 | 4 053 | 3 467 | — |
| Short-term debt | 59 630 | 15 637 | 26 885 | 20 639 | — |
| Total debt | 64 448 | 16 937 | 30 938 | 24 106 | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AH Chief Executive Officer | Chief Executive Officer | 2021 |
JO Chief Auditor | Chief Auditor | 2021 |
| Former (1) | ||
TW Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (7) | ||
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Board of Directors | 2021 | |
| Former (6) | ||
| Chairman | 2022 – 2025 | |
| Board of Directors | 2021 – 2024 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2021 – 2025 | |
| Chairman | 2021 – 2022 | |
| Board of Directors | 2021 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Moberg Pharma AB (publ) 
Moberg Derma Incentives ABBoard members of Moberg Pharma AB (publ) also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Torbjörn Widar Torsten Wärnheim | Chief Executive Officer | 0 companies |
| Anna Helena Constance Ljung | Chief Executive Officer | 0 companies |
| Jens Oscar Simon Bertling | Chief Auditor | 0 companies |
| Kerstin B Valinder Strinnholm | Chairman | 0 companies |
| Sven Anders Lundmark | Board of Directors | 0 companies |
| Isabelle Valerie G Ducellier | Board of Directors | 0 companies |
| Jonas Göran Ekblom | Chairman | 0 companies |
| Karl Fredrik Otto Granström | Board of Directors | 0 companies |
| Håkan Karl Gustav Vallin | Board of Directors | 0 companies |
| Zhang,Mona Xuan | Board of Directors | 0 companies |
| Peter Gunnar Maurits Wolpert | Chairman | 0 companies |
| Huakun Ding | Board of Directors | 0 companies |
| Andrew Bennet Hochman | Board of Directors | 0 companies |
| Sten Gunnar Otto Skolling | Board of Directors | 0 companies |
| Per Fredrik Blom | Board of Directors | 0 companies |
| Nikolaj Arrild Sörensen | Board of Directors | 0 companies |